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Debridement is a central tenet in the 
management of prosthetic joint infections 
(PJIs). Modern debridement has three distinct 
stages: 1) surgical; 2) mechanical/physical; 
and 3) chemical.1 Given more recent under-
standing in the pathogenesis of PJI,2 the 
microscopic targeting of the bacterial biofilm 
and intracellular pathogens should also be 
included in the art of debridement.2,3 The 
adequacy of debridement is critical to the 
success of single- stage procedures, which 
have been shown to result in lower patient 
morbidity and healthcare costs.4 There is 
currently an unmet clinical need to optimize 
debridement in the management of PJI.
Surgical debridement
Novel ultrasonic cutting devices may be 
beneficial as they selectively apply high strain 
to hard tissues, while soft tissues such as liga-
ments and nerves can be deflected without 
damage.5
Mechanical/physical debridement
Non- contact induction heating of metal 
prostheses delivers localized thermal damage 
to the biofilm, resulting in bacterial eradi-
cation and antibiotic synergism.6-8 Pulsed 
electromagnetic fields are used to induce 
eddy currents within metallic prostheses to 
generate heat.7 Low- intensity pulsed ultra-
sound potentiates antimicrobials when used 
against biofilms,3 as well as increasing the 
in vitro elution of antimicrobials from poly-
methylmethacrylate cement.9,10
Chemical debridement
Topical antiseptic agents, such as Beta-
dine, are only partially effective in 
the eradication of bacterial biofilms.11 
Ethylenediaminetetraacetic acid (EDTA) is 
a safe and effective debridement adjunct 
against multidrug- resistant pathogens in 
implant- related infections.12 EDTA, similar 
to acetic acid,11,13 already has regulatory 
approval for its use in the management of 
superficial wound infections.14
Biological debridement
There has been a renewed interest in bacte-
riophage therapy due to the pending global 
crisis in antimicrobial resistance.15 Bacterio-
phages are viruses that infect and inactivate 
bacteria. Unlike traditional antibiotics, bacte-
riophage activity is not limited by bacterial 
cell dormancy, furthermore the biological 
cost of acquired resistance to bacteriophages 
permits phage- susceptible clones to persist 
within wild- type populations.15 Host cell 
internalization allows pathogens to avoid 
antimicrobial exposure and immune system 
interaction. One strategy to overcome this 
problem is the addition of cell- penetrating 
peptides to both established antimicro-
bials and novel therapeutics.16 A further 
approach is the development of liposome 
nanocarriers, which are phospholipid vesi-
cles that are able to penetrate both biofilms 
and mammalian cells.17 Modified delivery 
systems using cell- penetrating peptides 
or liposome nanocarriers would allow co- 
localization of antimicrobial agents with 
intracellular pathogens. Monoclonal anti-
bodies that target matrix components of 
biofilms such as extracellular DNA, virulence 
factors, and adhesion factors can disperse 
established biofilms,18 act synergistically 
with established antimicrobials to eradi-
cate pathogens,18 and even inhibit biofilm 
formation.19
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